US EditionPublished • loading... • Updated
Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA
- Viva Biotech uses NVIDIA technology and the Proteina-Complexa model to design mini-binders targeting ActRIIA, aiming to accelerate AI-driven drug discovery for muscle wasting and lean mass imbalance diseases.
- The company employs a 'Lab-in-the-Loop' workflow that integrates computational design with high-throughput protein production and biophysical evaluation to develop ActRIIA binders.
- Their integrated approach combines in silico predictions with experimental validation, demonstrating the effectiveness of NVIDIA BioNeMo and Viva Biotech's AI platform in optimizing drug candidates.
- Viva Biotech leverages AI techniques for sequence selection and model feedback to explore new chemical spaces and improve design specificity more efficiently and cost-effectively than traditional methods.
Insights by Ground AI
45 Articles
45 Articles
Bennington Banner+44 Reposted by 44 other sources
Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA
SHANGHAI, March 16, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to…
Coverage Details
Total News Sources45
Leaning Left6Leaning Right7Center13Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 23%
C 50%
R 27%
Factuality
To view factuality data please Upgrade to Premium
